Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006002 · ClinicalTrials.gov registry record · Phase 2
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00006002 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 36 participants.
The verdict
NCT00006002, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells. It is not yet known whether SU5416 or dexamethasone is more effective in treating progressive prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of SU5416 with that of dexamethasone in treating patients who have progressive prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG dexamethasone
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2000-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006002
The ClinicalTrials.gov registry entry for NCT00006002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00006002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006002 about?
NCT00006002 is a clinical study titled "SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells. It is not yet known whether SU5416 or dexamethasone is more effective in treating progressive prostate cancer. PURPOSE: Random...
What is the current status of trial NCT00006002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2000-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00006002?
The interventions under investigation include: dexamethasone (DRUG), semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006002?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.